Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Total Non-Current Liabilities (2016 - 2025)

Apyx Medical's Total Non-Current Liabilities history spans 14 years, with the latest figure at $51.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 2.81% year-over-year to $51.7 million; the TTM value through Dec 2025 reached $51.7 million, up 2.81%, while the annual FY2025 figure was $51.7 million, 2.81% up from the prior year.
  • Total Non-Current Liabilities reached $51.7 million in Q4 2025 per APYX's latest filing, up from $51.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $52.1 million in Q4 2023 to a low of $10.8 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $31.4 million, with a median of $25.6 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: decreased 5.12% in 2022, then soared 277.65% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $14.5 million in 2021, then fell by 5.12% to $13.8 million in 2022, then skyrocketed by 277.65% to $52.1 million in 2023, then decreased by 3.59% to $50.2 million in 2024, then grew by 2.81% to $51.7 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Total Non-Current Liabilities are $51.7 million (Q4 2025), $51.0 million (Q3 2025), and $50.4 million (Q2 2025).